Do GLP‑1 receptor agonists cause cancer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

GLP-1 Receptor Agonists Do Not Cause Cancer in Humans

Based on the most authoritative evidence from the 2022 American Association of Clinical Endocrinology guidelines, there is no evidence that GLP-1 receptor agonists increase cancer risk in humans, and they may actually reduce the risk of certain obesity-associated cancers. 1

The Evidence on Cancer Risk

Pancreatic Cancer: No Causal Link

Early concerns about pancreatic cancer were raised by a single study showing pancreatic changes in humans on incretin therapy. However, comprehensive reviews by both the FDA and European Medicines Agency found no evidence supporting a causal association 1. Multiple meta-analyses of large placebo-controlled trials have confirmed no increased risk of pancreatic cancer with GLP-1 RAs 1.

Thyroid Cancer: Rodent Findings Don't Apply to Humans

While rodent studies showed thyroid C-cell tumors with liraglutide and exenatide, this finding does not translate to humans because human C-cells do not express GLP-1 receptors like rodent C-cells do 1. Placebo-controlled clinical trial data show no evidence of increased calcitonin or C-cell neoplasia in humans, and meta-analyses have found no increased risk for thyroid cancer 1.

Despite this reassuring evidence, GLP-1 RAs remain contraindicated in patients with:

  • Personal or family history of medullary thyroid carcinoma
  • Multiple endocrine neoplasia syndrome type 2

This is a precautionary measure based on the rodent data, not human evidence 1, 2.

Emerging Evidence of Cancer Risk Reduction

Recent high-quality observational studies suggest GLP-1 RAs may actually reduce cancer risk:

  • A 2025 study of 86,632 matched adults found GLP-1 RA use associated with 17% lower overall cancer risk (HR 0.83), with specific reductions in endometrial cancer (HR 0.75), ovarian cancer (HR 0.53), and meningioma (HR 0.69) 3

  • A 2024 study of 1.65 million patients with type 2 diabetes showed significant risk reductions in 10 of 13 obesity-associated cancers when comparing GLP-1 RAs to insulin, including gallbladder (HR 0.35), pancreatic (HR 0.41), hepatocellular (HR 0.47), ovarian (HR 0.52), and colorectal cancer (HR 0.54) 4

  • A 2026 meta-analysis of observational studies confirmed protective effects against colorectal (RR 0.54), liver (RR 0.35), and pancreatic cancer (RR 0.41) 5

Clinical Implications

You can confidently prescribe GLP-1 RAs without concern for causing cancer. The weight of evidence from guideline-level reviews, regulatory agencies, and large-scale studies supports their safety profile regarding cancer risk.

Key Practice Points:

  • No routine cancer monitoring is needed for patients on GLP-1 RAs—the FDA explicitly states that calcitonin monitoring is not required 1

  • Screen for contraindications: Ask about personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2 before prescribing

  • Consider potential benefits: In patients with obesity and diabetes, GLP-1 RAs may provide cancer risk reduction as an additional benefit beyond glycemic control and cardiovascular protection

  • Pancreatitis remains a consideration: While not cancer-related, monitor for signs of pancreatitis and discontinue if suspected, though a causal relationship has not been established 2

The convergence of guideline recommendations, regulatory reviews, and emerging real-world data provides strong reassurance that GLP-1 RAs do not cause cancer in humans and may offer protective effects against certain obesity-associated malignancies.

References

1
Guideline

american association of clinical endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan-2022 update.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2022

2
Guideline

clinical and investigative endocrinology and diabetes.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2018

Related Questions

Is osteosarcoma a contraindication to glucagon-like peptide‑1 (GLP‑1) receptor agonist therapy?
In a man with prostate cancer on androgen‑deprivation therapy who also has diabetes or obesity, should I continue or start a GLP‑1 receptor agonist, and what dosing and monitoring are recommended?
Can a patient with a history of melanoma in situ take Glucagon-like peptide-1 (GLP-1) receptor agonists, such as liraglutide (Victoza) or semaglutide (Ozempic), for type 2 diabetes management?
Is it safe for a patient with Lynch syndrome to use GLP‑1 receptor agonist medications?
What is the risk of medullary thyroid carcinoma associated with glucagon-like peptide‑1 (GLP‑1) receptor agonist therapy?
What is the appropriate management for a 4-year-old girl who ingested a pearl and now presents with abdominal pain?
How should nausea be managed in a pregnant patient?
In an adult with schizophrenia and depressive symptoms, is paliperidone (Invega) or risperidone more effective for treating depression and negative symptoms?
When should inflammatory bowel disease be suspected?
What imaging modality is preferred for detecting kidney stones?
What is the most appropriate next step in evaluating a 27-year-old man with mild jaundice?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.